TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10748772
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg/kg i.v. 5 minutes before induction of anaesthesia (before skin incision)
Study: 10748772
Drug: Pethidine administered
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine administered intraoperatively
Study: 10748772
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic requirements
Study: 8768686
Drug: Taped music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taped music and a message from their physicians during the next four chemotherapy treatments (n = 47)
Study: 1673587
Drug: Intravenous xamoterol
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous xamoterol
Study: 1673587
Drug: Oral xamoterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral xamoterol, 200 mg twice daily
Study: 1673587
Drug: Oral xamoterol
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral xamoterol
Study: 30801699
Drug: High-dose adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenocorticotropic hormone (ACTH)
Study: 30801699
Drug: High-dose adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenocorticotropic hormone (ACTH) without prior vigabatrin (VGB)
Study: 30801699
Drug: High-dose adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenocorticotropic hormone (ACTH) with prior vigabatrin (VGB)
Study: 27364900
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg IR/ER every 12 hours
Study: 27364900
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen 200 mg IR every 4 hours
Study: 27364900
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg IR/ER with food
Study: 27364900
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ibuprofen IR/ER
Study: 21289620
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral synthetic THC
Study: 21289620
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral synthetic THC
Study: 3240842
Drug: 10% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% protein diet (0.9 +/- 0.06 g.kg‐1.day‐1)
Study: 3240842
Drug: 20% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% protein diet (1.9 +/- 0.1 g.kg‐1.day‐1)
Study: 29330997
Drug: Various Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various Vitamin D3 preparations (Cholecalciferol) administered orally and intramuscularly
Study: 17023868
Drug: Methylphenidate at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for approximately 1 year
Study: 17023868
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment for 95 children who remained on medication
Study: 3929320
Drug: Chronic lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic lithium treatment
Study: 3929320
Drug: Other psychoactive
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other psychoactive drugs (not specified)
Study: 22978101
Drug: CM +
Normalized name: Trametes versicolor strain CM-101 extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM + chemotherapy
Study: 10233188
Drug: OAM =
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OAM = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Study: 10233188
Drug: RAM =
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAM = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + metronidazole 500 mg b.d.
Study: 10233188
Drug: OAC =
Normalized name: Oral Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC = omeprazole 20 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Study: 10233188
Drug: RAC =
Normalized name: Ractopamine
DrugBank: Ractopamine (DB11541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC = ranitidine 300 mg b.d. + amoxycillin 1 g b.d. + clarithromycin 250 mg t.d.s.
Study: 8904327
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g EACA upon initiation of cardiopulmonary bypass (CPB)
Study: 8904327
Drug: No antifibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifibrinolytic drugs prior to CPB
Study: 27002280
Drug: PA32540 (enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg)
Study: 27002280
Drug: EC-ASA (enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-ASA (enteric-coated aspirin 325 mg)
Study: 24385131
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low doses of ethanol (<5 mM blood concentration)
Study: 22179861
Drug: Oxycodone (Opioid)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (Opioid)
Study: 14693590
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg 2% preservative-free 2-chloroprocaine
Study: 14693590
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg 2% lidocaine
Study: 12378742
Drug: Atovaquone +
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone + proguanil combination
Study: 2547950
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 to 100 mg daily)
Study: 327854
Drug: Hydroxyzine HCl
Normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine HCl (50 mg)
Study: 31788318
Drug: Dotinurad (0.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotinurad (0.5-20 mg single-dose administration)
Study: 26480553
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding therapy applied to Qugu (CV 2), Shenshu (BL 23), Zhibian (BL 54), Huiyin (CV 1) and Sanyinjiao (SP 6), once every two weeks for 4 weeks, with two sessions total.
Study: 26480553
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group: tamsulosin capsules 0.2 mg once daily and indometacin sustained release tablets 25 mg three times daily for 8 weeks.
Study: 15279041
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with first generation agents
Study: 8305125
Drug: CRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH plus TRH administration
Study: 3423736
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking after cimetidine pretreatment (2 X 400 mg orally for 2 days and 400 mg orally 1.5 h before examination)
Study: 30986958
Drug: Pistachios (56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachios (56 g, 1318 kJ)
Study: 30986958
Drug: Savory biscuits
Normalized name: winter savory oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savory biscuits (56 g, isoenergetic/equiprotein)
Study: 28196772
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Group therapy (ACT‐G)
Study: 21592186
Drug: Cryotherapy gel
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy gel wrap applied to lower leg skin for 30 minutes daily for four weeks
Study: 18269390
Drug: Starch solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch solutions
Study: 17278430
Drug: Chemotherapy (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (one course) for group B patients
Study: 17278430
Drug: Total chemotherapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total chemotherapy for group B patients
Study: 8491007
Drug: Coumadin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin (with heparin until oral anticoagulation established)
Study: 8491007
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with discontinuation of heparin)
Study: 30217640
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of vasoactive medication use (in days)
Study: 30217640
Drug: Cumulative norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative norepinephrine dose (μg/kg/d)
Study: 26888712
Drug: DIET (25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIET (25% daily needs energy deficits induced by diet only)
Study: 26888712
Drug: EX (25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX (25% daily needs energy deficits induced by exercise only)
Study: 22081005
Drug: Losartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan + Simvastatin (20 mg/day)
Study: 22081005
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Simvastatin (20 mg/day)
Study: 20171410
Drug: Carbomer-based lipid-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer-based lipid-containing gel (CBLC)
Study: 20171410
Drug: HP-guar gel
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-guar gel
Study: 18165396
Drug: Raloxifene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (180 mg daily)
Study: 11576046
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% plus hyaluronidase 100 i.u. ml‐1
Study: 11576046
Drug: mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture of lidocaine 2% and bupivacaine 0.5% (2:3 volume per volume) containing hyaluronidase 25 i.u. ml‐1
Study: 8140940
Drug: NaF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF at 75 mg/day
Study: 3395500
Drug: Weekly prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly prescription for BSE
Study: 3395500
Drug: Every-two-weeks prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every-two-weeks prescription for BSE
Study: 3395500
Drug: Monthly prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly prescription for BSE
Study: 28626213
Drug: Imrecoxib 200
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Imrecoxib 200 mg twice daily
Study: 16575010
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2 IV daily for 5 days every 4 weeks)
Study: 16575010
Drug: CVP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVP (cyclophosphamide 750 mg/m2 IV on day 1; vincristine 1.4 mg/m2 IV on day 1; prednisone 40 mg/m2 orally on days 1-5 every 4 weeks)
Study: 10690763
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI, 1 sperm injected)
Study: 9139174
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of hot red pepper
Study: 29735470
Drug: Oral ulcer
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral ulcer powder combined with Kangfuxin liquid
Study: 22759259
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxylapatite (CaHA) injections
Study: 12595874
Drug: Transcranial electrostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial electrostimulation treatment (TCET)
Study: 11013193
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1% (20 patients)
Study: 8628597
Drug: Lovastatin 10
Normalized name: lovastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 10 mg/d
Study: 8628597
Drug: Lovastatin 30
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin 30 mg/d
Study: 1484946
Drug: Ice/slush topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice/slush topical hypothermia (Group I)
Study: 1484946
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical hypothermia (Group II)
Study: 3883733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of molsidomine three times daily
Study: 3883733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of molsidomine six times daily
Study: 3883733
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of molsidomine
Study: 3883733
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of sustained-release molsidomine
Study: 3883733
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of molsidomine four times daily
Study: 26888217
Drug: Everolimus (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (starting dose 1.5 mg/day; C0 3‐8 ng/mL) with cyclosporine
Study: 26888217
Drug: Everolimus (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (starting dose 3 mg/day; C0 3‐8 ng/mL) with tacrolimus
Study: 26888217
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (1.44 g/day or 2 g/day) with tacrolimus
Study: 21142632
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy (50 IU/kg/week) for 2 weeks
Study: 17705013
Drug: Pelvic SPECT
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic SPECT preceded by IV injection of 0.5 mg/kg furosemide and IV infusion of 500 cc saline (Group II)
Study: 15728297
Drug: L-arginine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine administered intravenously at the acute phase or orally at the interictal phase
Study: 15728297
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of L-arginine within 30 minutes of a stroke
Study: 11927706
Drug: Carnitine supplementation
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carnitine supplementation (30 mg/kg/d)
Study: 7610591
Drug: Topical non-selective
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical non-selective and selective beta-adrenoceptor antagonists
Study: 2116265
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition (IVN) support
Study: 2116265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous nutrition)
Study: 216027
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MSH/ACTH4-10
Study: 216027
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg MSH/ACTH4-10
Study: 24072634
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone combined with transdermal oestradiol
Study: 24072634
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate combined with transdermal oestradiol
Study: 18931824
Drug: TG4010 10(8)
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 10(8) pfu weekly for 6 weeks, then every 3 weeks
Study: 16393600
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream once daily for 1 month after curettage and electrodesiccation (C&D)
Study: 16393600
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream once daily for 1 month after curettage and electrodesiccation (C&D)
Study: 11060828
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride with statins (lovastatin, simvastatin, atorvastatin)
Study: 8828781
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rHuEPO into the venous drip chamber using the Fresenius delivery system
Study: 8828781
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rHuEPO into the venous port
Study: 8828781
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of rHuEPO into the venous drip chamber
Study: 1444083
Drug: Topical atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atropine immediately after trabeculectomy
Study: 1444083
Drug: Topical atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atropine beginning treatment on the first postoperative day
Study: 3894258
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid (600 mg daily)
Study: 3894258
Drug: ibuprofen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen (1.2 g daily)
Study: 28650195
Drug: Mindfulness-based addiction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based addiction treatment (MBAT)
Study: 15284073
Drug: L‐NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (3 mg/kg during the initial 5 min and subsequent continuous infusion of 50 mug.kg(‐1).min(‐1) in saline)
Study: 9072590
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 alpha-reductase inhibitor)
Study: 29446445
Drug: Lenograstim 5
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim 5 µg/kg
Study: 29446445
Drug: Biosimilar filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biosimilar filgrastim 10 µg/kg
Study: 14635971
Drug: Standard asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard asthma care with information on the stepwise treatment approach, a written action plan, and inhaler technique training
Study: 9429041
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA fentanyl
Study: 8397997
Drug: Enalaprilat (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (2.5 mg intravenously)
Study: 3301709
Drug: l(‐)ephedrine hydrochloride
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l(‐)ephedrine hydrochloride (50 mg three times a day per os)
Study: 27289457
Drug: PENS of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENS of dermatome T6 with a self-applied patch associated with diet (group 2)
Study: 25071023
Drug: Exenatide (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (GLP-1 receptor agonist)
Study: 25071023
Drug: Exendin 9-39
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin 9-39 (GLP-1 receptor blockade)
Study: 16402745
Drug: Sequential recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential recall or serial position identification task
Study: 12732401
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg/daily)
Study: 12732401
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg/daily)
Study: 12732401
Drug: Fenofibrate plus
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate plus Coenzyme Q10 (200+200 mg daily)
Study: 9798024
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (500 mg twice a day for 14 days)
Study: 2349932
Drug: Aspartame (APM)
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (APM) sweetened soda (1150 g per day for 3 weeks)
Study: 2349932
Drug: High-fructose corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose corn syrup (HFCS) sweetened soda (1150 g per day for 3 weeks)
Study: 30587225
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg doxycycline
Study: 30587225
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg doxycycline
Study: 30587225
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg minocycline
Study: 30587225
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg minocycline
Study: 30587225
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg doxycycline and minocycline
Study: 30587225
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg doxycycline and minocycline
Study: 27525966
Drug: Vortioxetine (fixed-dose)
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine (fixed-dose)
Study: 24326004
Drug: Glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine insulin delivery by pen device
Study: 24326004
Drug: Glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine insulin delivery by vial/syringe
Study: 24326004
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for insulin delivery method
Study: 23676198
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (subanesthetic dose)
Study: 18477227
Drug: 2.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg/day cyclosporin (CsA) treatment